HUP0500241A2 - Polimorf 4-{2-[4-[1-(2-etoxietil)-1H-benzimidazol-2-il]-1-piperidinil]etil}-alfa,alfa-dimetil-benzenoecetsav, eljárás előállításukra, az ezt tartalmazó gyógyszerkészítmények és alkalmazása - Google Patents

Polimorf 4-{2-[4-[1-(2-etoxietil)-1H-benzimidazol-2-il]-1-piperidinil]etil}-alfa,alfa-dimetil-benzenoecetsav, eljárás előállításukra, az ezt tartalmazó gyógyszerkészítmények és alkalmazása

Info

Publication number
HUP0500241A2
HUP0500241A2 HU0500241A HUP0500241A HUP0500241A2 HU P0500241 A2 HUP0500241 A2 HU P0500241A2 HU 0500241 A HU0500241 A HU 0500241A HU P0500241 A HUP0500241 A HU P0500241A HU P0500241 A2 HUP0500241 A2 HU P0500241A2
Authority
HU
Hungary
Prior art keywords
alpha
polymorph
ethoxyethyl
piperidinyl
ethyl
Prior art date
Application number
HU0500241A
Other languages
English (en)
Inventor
Aurelio Orjales Venero
Maravillas Bordell Martín
Gonzalo Canal Mori
Haydée Blanco Fuente
Maria Luisa Lucero De Pablo
Victor Rubio Royo
Ramón Mosquera Pestana
Original Assignee
Faes Farma, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29225789&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0500241(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Faes Farma, S.A. filed Critical Faes Farma, S.A.
Publication of HUP0500241A2 publication Critical patent/HUP0500241A2/hu
Publication of HU230032B1 publication Critical patent/HU230032B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A találmány tárgyát az (I) képletű 4-{2-[4-[1-(2-etoxietil)-1H-benzimidazol-2-il]-1-piperidinil]etil}-a,a-dimetil-benzenoecetsav(<bilasztin<) új polimorf kristályos formája képezi. A találmányhoztartoznak továbbá ezen vegyület előállítási eljárásai, az újpolimorfot tartalmazó gyógyászati készítmények és az új polimorfalkalmazása allergiás reakciók és hisztamin által mediált patológiásfolyamatok kezelésére használható gyógyszerkészítmények előállítására. Ó
HU0500241A 2002-04-19 2002-04-19 Polimorf 4-{2-[4-[1-(2-etoxietil)-1H-benzimidazol-2-il]-1-piperidinil]etil}-alfa,alfa-dimetil-benzenoecetsav HU230032B1 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/ES2002/000194 WO2003089425A1 (es) 2002-04-19 2002-04-19 POLIMORFO DEL ÁCIDO 4-[2-[4-[1-(2-ETOXIETIL)-1H-BENCIMIDAZOL-2-IL]-1-PIPERIDINIL]ETIL]-α, α-DIMETIL-BENCENOACÉTICO

Publications (2)

Publication Number Publication Date
HUP0500241A2 true HUP0500241A2 (hu) 2005-06-28
HU230032B1 HU230032B1 (hu) 2015-05-28

Family

ID=29225789

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0500241A HU230032B1 (hu) 2002-04-19 2002-04-19 Polimorf 4-{2-[4-[1-(2-etoxietil)-1H-benzimidazol-2-il]-1-piperidinil]etil}-alfa,alfa-dimetil-benzenoecetsav

Country Status (31)

Country Link
US (2) US7612095B2 (hu)
EP (1) EP1505066B1 (hu)
JP (1) JP5142448B2 (hu)
KR (1) KR100673140B1 (hu)
CN (1) CN1290843C (hu)
AR (1) AR039423A1 (hu)
AT (1) ATE347550T1 (hu)
AU (1) AU2002255017B2 (hu)
BG (1) BG66302B1 (hu)
BR (1) BRPI0215703B8 (hu)
CA (1) CA2484460C (hu)
CY (2) CY1107564T1 (hu)
CZ (1) CZ305162B6 (hu)
DE (1) DE60216641T2 (hu)
DK (1) DK1505066T3 (hu)
ES (1) ES2278018T3 (hu)
HK (1) HK1072772A1 (hu)
HR (1) HRP20041048B1 (hu)
HU (1) HU230032B1 (hu)
IL (1) IL164645A (hu)
MX (1) MXPA04010313A (hu)
NO (1) NO329327B1 (hu)
NZ (1) NZ536551A (hu)
PA (1) PA8571201A1 (hu)
PE (1) PE20040086A1 (hu)
PT (1) PT1505066E (hu)
SI (1) SI1505066T1 (hu)
SK (1) SK288052B6 (hu)
UA (1) UA76866C2 (hu)
UY (1) UY27762A1 (hu)
WO (1) WO2003089425A1 (hu)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010013472A (ja) * 2009-09-09 2010-01-21 Faes Farma Sa ４−［２−［１−（２−エトキシエチル）−１Ｈ−ベンズイミダゾール−２−イル］−１−ピペリジニル］エチル］−α，α−ジメチルベンゼノ酢酸の多形体
WO2013001731A1 (ja) * 2011-06-30 2013-01-03 パナソニック株式会社 通信システム、ユーザ端末並びに通信装置
CN102675101B (zh) * 2012-05-16 2014-01-29 王蕾 2-(4-卤乙基)苯基-2-甲基丙酸酯的制备方法及合成比拉斯汀的方法
CZ307500B6 (cs) 2012-08-15 2018-10-24 Zentiva, K.S. Způsob přípravy derivátu 2-methyl-2´-fenylpropionové kyseliny využívající nové intermediáty
CN103214454A (zh) * 2013-03-30 2013-07-24 北京万全德众医药生物技术有限公司 一种比拉斯汀晶型及制备方法
WO2014188453A2 (en) * 2013-05-24 2014-11-27 Msn Laboratories Private Limited Novel process for the preparation of 2-[4-(2-{4-[1-(2-ethoxyethyl)-1h-benzimidazol-2-yl]-1-piperidinyl}ethyl) phenyl]-2-methylpropanoic acid
CN103356616A (zh) * 2013-06-29 2013-10-23 北京万全德众医药生物技术有限公司 一种含有比拉斯汀的药物组合物及其制备方法
CN104447682A (zh) * 2013-09-12 2015-03-25 天津市汉康医药生物技术有限公司 比拉斯汀化合物
CN104398481A (zh) * 2014-10-29 2015-03-11 万全万特制药江苏有限公司 比拉斯汀口崩片及其制备方法
CA2993134A1 (en) * 2015-07-24 2017-02-02 Urquima, S.A. Crystalline forms of bilastine and preparation methods thereof
EP3170817A1 (en) 2015-11-20 2017-05-24 Faes Farma, S.A. Co-crystals of benzimidazole compounds
EP3170816A1 (en) * 2015-11-20 2017-05-24 Faes Farma, S.A. Supersaturated compositions of benzimidazole compounds
WO2017167949A1 (en) 2016-04-01 2017-10-05 Krka, D.D., Novo Mesto Crystalline forms of bilastine
WO2017191651A1 (en) * 2016-05-05 2017-11-09 Msn Laboratories Private Limited, R & D Center Solid state forms of 2-[4-(2-{4-[1-(2-ethoxyethyl)-1h-benzimidazol-2-yl]-1-piperidinyl}ethyl)phenyl]-2-methylpropanoic acid and process for preparation thereof
EP3453384B1 (en) 2017-09-07 2020-05-27 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical tablet composition comprising bilastine
EP3641735B1 (en) * 2017-12-18 2021-02-24 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical tablet composition comprising bilastine form 3 and a water-soluble filler
EP3470062B1 (en) 2017-12-18 2020-10-28 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical tablet composition comprising bilastine polymorphic form 3 and magnesium aluminometasilicate
WO2019141563A1 (en) 2018-01-18 2019-07-25 Faes Farma, S.A. Ophthalmic compositions comprising bilastine, a beta-cyclodextrin and at least one gelling agent
CA3200779A1 (en) 2020-12-23 2022-06-30 Strusi ORAZIO LUCA A non-micronized bilastine composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810789A (en) * 1987-08-28 1989-03-07 Bristol-Myers Company Process for buspirone hydrochloride polymorphic crystalline form conversion
ES2124167B1 (es) * 1996-06-04 1999-09-16 Espanola Prod Quimicos Nuevos derivados del bencimidazol con actividad antihistaminica.
BR0010683A (pt) * 1999-04-16 2003-07-01 Reddy Research Foundation Formas polimórficas de um agente antidiabético: processo para seu preparo e composições farmacêuticas contendo o mesmo
CO5170421A1 (es) * 1999-04-23 2002-06-27 Smithkline Beecham Plc Nuevo compuesto farmaceutico maleico

Also Published As

Publication number Publication date
UY27762A1 (es) 2003-09-30
IL164645A0 (en) 2005-12-18
EP1505066A1 (en) 2005-02-09
BRPI0215703B8 (pt) 2021-05-25
PA8571201A1 (es) 2003-12-10
BRPI0215703B1 (pt) 2017-06-27
NO20044999L (no) 2005-01-14
CY2013015I2 (el) 2015-08-05
ATE347550T1 (de) 2006-12-15
CZ305162B6 (cs) 2015-05-27
CA2484460A1 (en) 2003-10-30
SK50202004A3 (sk) 2005-05-05
CY1107564T1 (el) 2013-03-13
PE20040086A1 (es) 2004-04-27
DK1505066T3 (da) 2007-03-19
BG108941A (en) 2005-12-30
KR20050005448A (ko) 2005-01-13
UA76866C2 (uk) 2006-09-15
DE60216641D1 (de) 2007-01-18
SK288052B6 (sk) 2013-03-01
BG66302B1 (bg) 2013-03-29
US20050203141A1 (en) 2005-09-15
SI1505066T1 (sl) 2007-04-30
PT1505066E (pt) 2007-03-30
HRP20041048A9 (hr) 2013-01-31
MXPA04010313A (es) 2005-06-08
CY2013015I1 (el) 2015-08-05
HK1072772A1 (en) 2005-09-09
ES2278018T3 (es) 2007-08-01
HRP20041048B1 (hr) 2013-04-30
HU230032B1 (hu) 2015-05-28
IL164645A (en) 2010-11-30
AU2002255017A1 (en) 2003-11-03
JP2005529120A (ja) 2005-09-29
US7612095B2 (en) 2009-11-03
JP5142448B2 (ja) 2013-02-13
AR039423A1 (es) 2005-02-16
CN1628112A (zh) 2005-06-15
NO329327B1 (no) 2010-09-27
CN1290843C (zh) 2006-12-20
WO2003089425A1 (es) 2003-10-30
BR0215703A (pt) 2005-02-01
CA2484460C (en) 2009-09-29
NZ536551A (en) 2006-08-31
KR100673140B1 (ko) 2007-01-22
HRP20041048A2 (en) 2005-02-28
US20100004285A1 (en) 2010-01-07
DE60216641T2 (de) 2007-09-27
AU2002255017B2 (en) 2008-11-13
EP1505066B1 (en) 2006-12-06
CZ20041122A3 (cs) 2005-03-16

Similar Documents

Publication Publication Date Title
HUP0500241A2 (hu) Polimorf 4-{2-[4-[1-(2-etoxietil)-1H-benzimidazol-2-il]-1-piperidinil]etil}-alfa,alfa-dimetil-benzenoecetsav, eljárás előállításukra, az ezt tartalmazó gyógyszerkészítmények és alkalmazása
JP6483146B2 (ja) アルツハイマー病治療用のｂａｃｅ１阻害剤としての２−アミノ−３，５，５−トリフルオロ−３，４，５，６−テトラヒドロピリジン
NO20055068L (no) Kjemiske forbindelser
NO20075365L (no) 3,4-substituerte pyrrolidinderivater for behandling av hypertensjon
DE60315323D1 (de) Piperidinderivate zur verwendung bei der behandlung von durch chemokins vermittelten leiden
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
BRPI0514865A (pt) processo para preparar um composto
MXPA04003007A (es) Compuestos azabiciclico sustituidos condensados con heteroarilo para el tratamiento de enfermedades.
HUP0402043A2 (hu) Rimonabant polimorf formája, eljárás ezen forma előállítására és ilyen polimorf formát tartalmazó gyógyászati készítmények
EP2423207A3 (en) 2-(cyclic amino)-pyrimidone derivatives as TPK1 inhibitors
NO20050741L (no) Ny fremgangsmate for syntesen og ny krystallinsk form av agomelatin og farmasoytiske sammensetninger inneholdende den
PE20050078A1 (es) Derivados de pirrolidona como inhibidores de maob
CA2753434A1 (en) Soluble guanylate cyclase activators
SE0301368D0 (sv) Chemical compounds
HUP0401886A2 (hu) Kemokin receptor aktivitás modulátorokként alkalmazható piperidinszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
TW200740779A (en) Intermediate compound for synthesizing pharmaceutical agent and production method thereof
EP2412707A3 (en) 3-[2-(3-Amino-2-oxo-2H-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors
NO20073839L (no) Kinolinderivat, fremgangsmate for fremstilling og anvendelse av dette, og legemiddel inneholdende dette
NO20063268L (no) Fremgangsmate til fremstilling av 1-(2S,3S)-2-benzhydryl-N-(5-tert-butyl-2-metoksybenzyl)quinuklidin-3-amin
NO20060417L (no) Fremgangsmate til fremstilling av 1-okten fra krakk-C4
CA2524900A1 (en) 6-cyclylmethyl- and 6-alkylmethyl-substituted pyrazolopyrimidines
MA27133A1 (fr) Nouvelles formes polymorphes cristallines d&#39;hydrochlorure de lercanidipine et procede de fabrication associe
HUP0303928A2 (hu) Omeprazol kristályos formája, eljárás az előállítására és ezt tartalmazó gyógyszerkészítmények
AU2003208686A1 (en) Alkylammonium salts of omeprazole and esomeprazole
DE60210977D1 (de) Immunmodulierende verbindungen